Mechanisms of Action of Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia - PubMed (original) (raw)
Mechanisms of Action of Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia
Guang-Sheng Lei et al. Antimicrob Agents Chemother. 2017.
Abstract
The combination of trimethoprim and sulfamethoxazole (TMP-SMX) is the most effective regimen for therapy of Pneumocystis pneumonia (PCP). As many patients with PCP are allergic or do not respond to it, efforts have been devoted to develop alternative therapies for PCP. We have found that the combination of vitamin D3 (VitD3) (300 IU/kg/day) and primaquine (PMQ) (5 mg/kg/day) was as effective as TMP-SMX for therapy of PCP. In this study, we investigated the mechanisms by which vitamin D enhances the efficacy of PMQ. C57BL/6 mice were immunosuppressed by CD4+ cell depletion, infected with Pneumocystis murina for 8 weeks, and then treated for 9 days with the combination of VitD3 and PMQ (VitD3-PMQ) or with TMP-SMX or PMQ to serve as controls. The results showed that vitamin D supplementation increased the number of CD11c+ cells, suppressed the production of proinflammatory cytokines (tumor necrosis factor alpha [TNF-α], gamma interferon [IFN-γ], and interleukin-6 [IL-6]) and inducible nitric oxide synthase (iNOS), and enhanced the expression of genes related to antioxidation (glutathione reductase and glutamate-cysteine ligase modifier subunit), antimicrobial peptides (cathelicidin), and autophagy (ATG5 and beclin-1). These results suggest that the main action of vitamin D is enhancing the ability of the host to defend against Pneumocystis infection.
Keywords: Pneumocystis pneumonia; alveolar macrophages; vitamin D3.
Copyright © 2017 American Society for Microbiology.
Figures
FIG 1
Changes in body weight during therapy. Mice infected with P. murina for 8 weeks were treated with TMP-SMX, PMQ, or VitD3-PMQ. Each mouse was weighed before and every 3 days after initiation of treatment for 9 days. Each dot represents the average body weight of 5 mice in various treatment groups.
FIG 2
Lung histopathology. H&E- and methenamine silver-stained lung sections of the following mouse groups are shown: immunosuppressed mice with PCP for 8 weeks (Untreated) and mice with PCP for 8 weeks treated with TMP-SMX, PMQ, or VitD3-PMQ for 9 days. (A) H&E-stained lung sections (magnification, ×100). Arrows indicate infiltrated inflammatory cells. (B) Methenamine silver-stained lung sections (magnification, ×200). Pneumocystis cysts are seen as black dots or clusters.
FIG 3
Cytokine levels in BAL fluids. The first 2 ml of BAL fluid was used for ELISA. (A) TNF-α levels in BAL fluids of immunosuppressed uninfected mice, mice with PCP, and mice with PCP treated with TMP-SMX, PMQ, or VitD3-PMQ. (B) IFN-γ levels in BAL fluids of various mouse groups. (C) IL-6 levels in BAL fluids of various mouse groups. ND, not detected. *, P < 0.05.
FIG 4
Histograms of CD11c+ cells from BAL fluids. Immunosuppressed mice were infected with P. murina for 8 weeks and then treated with TMP-SMX, PMQ, or VitD3-PMQ for 9 days. BAL fluid cells of mice in various groups were collected, stained with Alexa Fluor 647-labeled anti-CD11c antibodies, and then analyzed by flow cytometry. The percentage of CD11c+ cells in each group of mice is indicated.
FIG 5
Morphology of isolated CD11c+ cells. BAL fluid cells from mice with PCP treated with VitD3-PMQ for 9 days were collected. CD11c+ cells were isolated using biotin–anti-mouse CD11c antibody and antibiotin magnetic microbeads. Isolated cells were cytospun on slides, stained with Giemsa stain, and examined by light microscopy.
FIG 6
Expression levels of stress genes. Thirty milligrams of lung tissue from each mouse in various treatment groups was placed in 600 μl RLT buffer (RNeasy minikit; Qiagen) and homogenized. Total RNA was isolated and reverse transcribed to cDNA. mRNA levels of iNOS (A), GR (B), GCLM (C), CAMP (D), TLR2 (E), TLR4 (F), and NF-κB (G) were determined by SYBR green qRT-PCR. Data are presented as fold change (mean ± SD). *, P < 0.05.
FIG 7
Expression levels of autophagy markers. The converted cDNA as described for Fig. 6 was used to determine mRNA levels of ATG5 (A) and BCN1 (B). Data are presented as fold change (mean ± SD). *, P < 0.05.
Similar articles
- Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia.
Lei GS, Zhang C, Zimmerman MK, Lee CH. Lei GS, et al. Antimicrob Agents Chemother. 2015 Dec 14;60(3):1289-97. doi: 10.1128/AAC.02607-15. Antimicrob Agents Chemother. 2015. PMID: 26666941 Free PMC article. - All-trans retinoic acid in combination with primaquine clears pneumocystis infection.
Lei GS, Zhang C, Shao S, Jung HW, Durant PJ, Lee CH. Lei GS, et al. PLoS One. 2013;8(1):e53479. doi: 10.1371/journal.pone.0053479. Epub 2013 Jan 4. PLoS One. 2013. PMID: 23308231 Free PMC article. - Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients.
Nickel P, Schürmann M, Albrecht H, Schindler R, Budde K, Westhoff T, Millward J, Suttorp N, Reinke P, Schürmann D. Nickel P, et al. Infection. 2014 Dec;42(6):981-9. doi: 10.1007/s15010-014-0660-y. Epub 2014 Aug 29. Infection. 2014. PMID: 25168263 - Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case series and systematic review.
Benfield T, Atzori C, Miller RF, Helweg-Larsen J. Benfield T, et al. J Acquir Immune Defic Syndr. 2008 May 1;48(1):63-7. doi: 10.1097/QAI.0b013e31816de84d. J Acquir Immune Defic Syndr. 2008. PMID: 18360286 Review.
Cited by
- Role of vitamin D in COVID-19 and other viral infections.
Engin MMN, Özdemir Ö. Engin MMN, et al. World J Virol. 2024 Sep 25;13(3):95349. doi: 10.5501/wjv.v13.i3.95349. World J Virol. 2024. PMID: 39323448 Free PMC article. Review. - Correlation of vitamin D levels with serum parameters in Covid-19 patients.
Beheshti M, Neisi N, Parsanahad M, Rasti M, Nashibi R, Cheraghian B. Beheshti M, et al. Clin Nutr ESPEN. 2023 Jun;55:325-331. doi: 10.1016/j.clnesp.2023.04.012. Epub 2023 Apr 19. Clin Nutr ESPEN. 2023. PMID: 37202065 Free PMC article. - Relationship between Vitamin D and Immunity in Older People with COVID-19.
Lauretani F, Salvi M, Zucchini I, Testa C, Cattabiani C, Arisi A, Maggio M. Lauretani F, et al. Int J Environ Res Public Health. 2023 Apr 7;20(8):5432. doi: 10.3390/ijerph20085432. Int J Environ Res Public Health. 2023. PMID: 37107714 Free PMC article. Review. - Evaluation of the diagnosis and treatment options for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Kouhpayeh H. Kouhpayeh H. J Family Med Prim Care. 2022 Aug;11(8):4219-4227. doi: 10.4103/jfmpc.jfmpc_1735_21. Epub 2022 Aug 30. J Family Med Prim Care. 2022. PMID: 36352961 Free PMC article. Review. - Vitamin D-A prominent immunomodulator to prevent COVID-19 infection.
Ashique S, Gupta K, Gupta G, Mishra N, Singh SK, Wadhwa S, Gulati M, Dureja H, Zacconi F, Oliver BG, Paudel KR, Hansbro PM, Chellappan DK, Dua K. Ashique S, et al. Int J Rheum Dis. 2023 Jan;26(1):13-30. doi: 10.1111/1756-185X.14477. Epub 2022 Oct 29. Int J Rheum Dis. 2023. PMID: 36308699 Free PMC article. Review.
References
- CDC. 2014. Pneumocystis pneumonia statistics. http://www.cdc.gov/fungal/diseases/pneumocystis-pneumonia/statistics.html.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials